Valeo Pharma Inc. (VPH.TO)
| Previous Close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0600 x N/A |
| Ask | 0.0650 x N/A |
| Day's Range | 0.0500 - 0.0600 |
| 52 Week Range | 0.0500 - 0.3850 |
| Volume | |
| Avg. Volume | 38,027 |
| Market Cap | 5.919M |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3400 |
| Earnings Date | Sept 11, 2024 - Sept 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.40 |
- Baystreet
Stocks in play: Valeo Pharma Inc.
Announced that it has entered into an agreement with Sagard Healthcare Royalty Partners, LP, which amends ...
CNW GroupVALEO PHARMA AMENDS CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
Valeo Pharma Inc. (TSX: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the "Amendment") with Sagard Healthcare Royalty Partners, LP ("Sagard"), which amends the Secured Term Loan (the "Facility'') entered into between Valeo and Sagard in July 2022.
CNW GroupVALEO PHARMA ANNOUNCES VOLUNTARY DELISTING FROM OTCQB VENTURE MARKET
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that the Company is voluntarily delisting its Class A shares from trading on the OTCQB Venture Market due to low trading volume, the associated administrative requirements and costs and other corporate and commercial priorities. The Company's last day of trading on the OTCQB Venture Market will be August 30, 2024.
